Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
Medical Oncology (Northwood, London, England)
|
April 29, 2009
Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
Holger Gerullis, Lothar Bergmann, Luise Maute, et al.
Aktuelle Urologie
|
December 1, 2021
[Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma]
Kurt Miller, Lothar Bergmann, Christian Doehn, et al.
Journal of Cancer Research and Clinical Oncology
|
February 22, 2014
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis
Luise Maute, Viktor Grünwald, Steffen Weikert, et al.
Aktuelle Urologie
|
October 7, 2020
[Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma]
Kurt Miller, Lothar Bergmann, Christian Doehn, et al.
Future Oncology (London, England)
|
March 16, 2021
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry
Arne Strauss, Marianne Schmid, Michael Rink, et al.
Experimental Hematology
|
March 31, 2004
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells
Gabriele Hübinger, Christof Schneider, Dagmar Stöhr, et al.
Future Oncology (London, England)
|
October 6, 2020
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry
Martin Boegemann, Katrin Schlack, Michael Rink, et al.
Oncology Research and Treatment
|
January 19, 2022
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
Viktor Grünwald, Thomas Hilser, Johannes Meiler, et al.
Annals of Hematology
|
July 8, 2005
High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation
Gesine Bug, Johannes Atta, Stefan A Klein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 8, 2008
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)
Lothar Bergmann, Steiner Aamdal, Sandrine Marreaud, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
Medical Oncology (Northwood, London, England)
|
April 29, 2009
Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
Holger Gerullis, Lothar Bergmann, Luise Maute, et al.
Aktuelle Urologie
|
December 1, 2021
[Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma]
Kurt Miller, Lothar Bergmann, Christian Doehn, et al.
Journal of Cancer Research and Clinical Oncology
|
February 22, 2014
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis
Luise Maute, Viktor Grünwald, Steffen Weikert, et al.
Aktuelle Urologie
|
October 7, 2020
[Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma]
Kurt Miller, Lothar Bergmann, Christian Doehn, et al.
Future Oncology (London, England)
|
March 16, 2021
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry
Arne Strauss, Marianne Schmid, Michael Rink, et al.
Experimental Hematology
|
March 31, 2004
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells
Gabriele Hübinger, Christof Schneider, Dagmar Stöhr, et al.
Future Oncology (London, England)
|
October 6, 2020
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry
Martin Boegemann, Katrin Schlack, Michael Rink, et al.
Oncology Research and Treatment
|
January 19, 2022
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
Viktor Grünwald, Thomas Hilser, Johannes Meiler, et al.
Annals of Hematology
|
July 8, 2005
High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation
Gesine Bug, Johannes Atta, Stefan A Klein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 8, 2008
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)
Lothar Bergmann, Steiner Aamdal, Sandrine Marreaud, et al.
Page
of 5